Skip to content
← Full study record

NCT01202409 · OUTCOME

Overall Progression-free Survival (PFS) for CAPOX and Panitumumab

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater · Source last updated 2020-02-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
7.6 months

What was measured

Time interval in months from date of first treatment until the date of first documented progression of participants.

Groups in this outcome

Capecitabine + Panitumumab + Oxaliplatin

Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Panitumumab 9 mg/kg IV over 60 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Capecitabine + Panitumumab + Oxaliplatin13

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Capecitabine + Panitumumab + Oxaliplatin2.4Not reported17.6Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        7.6
        value
        2.4
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    units
    Participants
description
Time interval in months from date of first treatment until the date of first documented progression of participants.
dispersion Type
Full Range
groups
  1. description
    Capecitabine 750mg/m2 oral twice daily, Days 1 - 14 and Panitumumab 9 mg/kg IV over 60 minutes on Day 1 and Oxaliplatin 130 mg/m2 IV over 2 hours Day 1 of 21-day cycle.
    id
    OG000
    title
    Capecitabine + Panitumumab + Oxaliplatin
param Type
MEDIAN
reporting Status
POSTED
time Frame
7.6 months
title
Overall Progression-free Survival (PFS) for CAPOX and Panitumumab
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice